Latigo Biotherapeutics, Inc. (LTGO) Income Statement
LTGO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLTGO revenue and net income
LTGO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LTGO quarterly EPS vs estimates
Latigo Biotherapeutics beat the analyst EPS estimate in 0 of the last 1 quarters. Next report: December 3, 2026.
LTGO income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0 | $0 |
| Research & development | $99.5M | $56.8M |
| Sales, general & admin | $10.9M | $6.7M |
| Total operating expenses | $110.4M | $63.5M |
| Operating income | −$110.4M | −$63.5M |
| Interest income | $2.9M | $2.3M |
| Income before taxes | −$109.2M | −$61.2M |
| Net income | −$109.2M | −$61.2M |
| EBITDA | −$110.1M | −$63.2M |
| Jun '26 | Mar '26 | Jun '25 | Mar '25 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research & development | $21.2M | $17.6M | $22.9M | $18.7M |
| Sales, general & admin | $4.6M | $5.8M | $2.8M | $2.8M |
| Total operating expenses | $25.8M | $23.4M | $25.7M | $21.5M |
| Operating income | −$25.8M | −$23.4M | −$25.7M | −$21.5M |
| Interest income | $264,000 | $474,000 | $868,000 | $517,000 |
| Interest expense | $251,000 | — | $0 | — |
| Income before taxes | −$25.8M | −$23.0M | −$25.8M | −$21.0M |
| Net income | −$25.8M | −$23.0M | −$25.8M | −$21.0M |
| EBITDA | −$25.5M | −$23.4M | −$25.8M | −$21.4M |
| EPS (diluted) | −$27.59 | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LTGO's financial statements (latest annual report filed —); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LTGO financial results
Latigo Biotherapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $109.2 million.
See the LTGO stock overview for the latest quote and news, or the LTGO chart for price history and technical indicators.
LTGO income statement FAQ
Does Latigo Biotherapeutics have revenue?
Latigo Biotherapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Latigo Biotherapeutics profitable?
No. Latigo Biotherapeutics reported a net loss of $109.2 million in fiscal 2025.
How much does Latigo Biotherapeutics spend on research and development?
Latigo Biotherapeutics spent $99.5 million on research and development in fiscal 2025.
When will Latigo Biotherapeutics report its next earnings?
Latigo Biotherapeutics is expected to report results for the quarter ending September 30, 2026 on December 3, 2026.
When does Latigo Biotherapeutics's fiscal year end?
Latigo Biotherapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025.